[go: up one dir, main page]

WO2000060073A1 - Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique - Google Patents

Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique Download PDF

Info

Publication number
WO2000060073A1
WO2000060073A1 PCT/JP2000/001796 JP0001796W WO0060073A1 WO 2000060073 A1 WO2000060073 A1 WO 2000060073A1 JP 0001796 W JP0001796 W JP 0001796W WO 0060073 A1 WO0060073 A1 WO 0060073A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene
seq
sequence
irg27
Prior art date
Application number
PCT/JP2000/001796
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Enjoji
Naoki Tohdoh
Original Assignee
Sumitomo Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co., Ltd. filed Critical Sumitomo Pharmaceuticals Co., Ltd.
Publication of WO2000060073A1 publication Critical patent/WO2000060073A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Definitions

  • the present invention relates to the use of a gene that evolves when P53 force, which is a tumor suppressor, is inactivated, or an antibody against a polypeptide encoded by the gene, for cancer diagnosis.
  • P53 force which is a tumor suppressor
  • the expression of P53 is induced by inactivation of P53, and esophageal esophagus cancer, stomach cancer, lung cancer, kidney cancer, thyroid cancer, parotid gland cancer, ureteral cancer, bladder cancer, uterine cancer, liver cancer, breast cancer
  • IRG27 which is expressed in various human cancers such as ovarian cancer and fallopian tube cancer, and a novel cancer using the antibody against IRG27. Diagnostic agents and diagnostic methods. Background art
  • the object of the present invention is to provide a diagnostic agent for cancer and a method for diagnosing cancer, using a gene whose expression is increased upon inactivation by force or an antibody against a polypeptide encoded by the gene.
  • the expression power is induced by inactivation of the present invention 53, and Eating m, stomach cancer, lung cancer, ⁇ cancer, 3 ⁇ 4 »3 ⁇ 4, parotid, ureteral cancer, bladder cancer, uterine cancer, liver cancer, breast cancer, sickle, fallopian tube, etc.
  • An object of the present invention is to provide a novel diagnostic agent for cancer, a method for diagnosing cancer, and the like using a gene encoding a polypeptide designated as No. 27 and an antibody against IRG27.
  • the present inventors have considered using P53, which is a tumor suppressor gene product, for the development of a novel cancer diagnostic technique (tumor marker 1).
  • P53 gene The gene with the highest mutation level in a variety of human cancers.
  • the wild-type p53 gene was cloned and its function was confirmed.
  • wild-type p53 suppressed transformation (carcinogenesis), and the introduction of wild-type p53 resulted in tumorigenicity.
  • it is defined as a gene that has been deleted or inactivated in cancer cells, and the normal gene has the function of returning cancer cells to normal cells. It was found to be one of the “genes” (protein nucleic acid enzyme, 35: 54-55, 1990).
  • abnormalities are found in about 50% of cancers of all tissues, including liver and bladder cancers, and abnormalities in the p53 gene Is widely known to be deeply involved in the development and progression of cancer (Murakami I, eta 1., Am. J. Respirr. Crit. Carre. Med., 154, 1117-1123, 1996, Kang MS, eta 1., Int. J. Cancer, 67, 898-902, 1996, Uchida T, eta 1., J. Urol., 153, 1097-1104, 1995).
  • the p53 gene occurs more frequently during the carcinogenesis process before the cancer eradicates.
  • the present inventors have found high MJ3 ⁇ 4 gene abnormalities in such various cancers Focusing on P53, we examined factors that increase in expression due to p53 gene abnormality (p53 inactivation). That is, as a result of selecting genes that are specifically expressed in the fibril trait ⁇ ffl cells in which P53 was inactivated, we succeeded in obtaining a plurality of genes, and of these genes, IRG 27 (imm ortaliz at i It was found that the gene of the factor named on rel at edgene 27) was evolved along with inactivation of p53 and was elevated ⁇ in each S cell.
  • the present inventors obtained the finding that 17 of the 24 cancer patients (approximately 70%) showed that the IRG27 gene was elevated in the tumor part compared to the non-tumor part, and We found that it can be used for diagnosis of various cancers. Furthermore, the present inventors have prepared an antibody corresponding to the IRG27 polypeptide, and have shown that an antibody against the IRG27 polypeptide is also effective for cancer diagnosis.
  • the RG27 gene had high homology (98.1%) with the ISG20 gene whose expression was induced by interferon. It has been reported that it co-localizes with n SG 1 ear body along with I SG2C PM L and SP 100, but its function is unknown (Gongo ra C, eta 1., J. ⁇ i ⁇ 1. Chem , 272, 19457- 19463, 1997).
  • ISG20 from ⁇ BD audi ⁇ ⁇ IRG27 derived from human peripheral blood because it is a protein with two amino acid residues deleted compared to IRG27 from human peripheral blood leukocytes
  • the nucleotide sequences of the three clones encoding were cloned, and no amino acid sequence deletion was found in any of the clones.
  • mouse IRG27 had the same number of amino acid residues as human IRG27, IRG27 derived from human peripheral blood leukocytes had the original amino acid sequence, ISG20 obtained from Daudi cells was thought to have an amino acid sequence unique to Daudi cells.
  • HEM45 Pent ecost BT, J. Steroid Biochem. l. Biol., 64, 25-33, 1998.
  • ISO 20 and HEM 45 the relationship between the ISO 20 and HEM 45 was not known at all. That is, it has not been clarified that the expression is induced by the inactivation of P53 and that it is useful for diagnosis of various cancers.
  • the present invention has been completed based on the above findings.
  • (c) contains the nucleotide sequence of any one of SEQ ID NO: 14 to SEQ ID NO: 29
  • A or a diagnostic agent for cancer, comprising the target of these DNAs as the active ingredient.
  • SEQ ID NO: 3 to SEQ ID NO: 5 consisting of a sequence consisting of at least M 17 bases of the positive and reverse chains of the gene consisting of the base sequence described in the sequence or the allele mutant gene thereof
  • a diagnostic agent for cancer comprising strand or double-stranded DNA, or the labeling of these DNAs as an active ingredient.
  • a diagnostic agent for cancer comprising the antibody, antibody fragment, or derivative thereof according to any of (8) to (10) as an active ingredient.
  • the diagnostic agent for cancer according to any one of (1) to (7) or (11) is used.
  • a method of diagnosing cancer is used.
  • DNA which is an active ingredient of a diagnostic agent for cancer in the present invention, is expressed by (a) inactivation of tumor suppressor P53, and (b) cancer compared to normal thread.
  • (a) a gene whose expression is induced by inactivation of the tumor suppressor p53 can be isolated, for example, by a method including the following steps A to E.
  • the mutant or deleted p53 gene used in the above step A is a normal p53 gene (Mol.Cell.Biol., 7, p961 (1987), Japanese Cancer Research Resources Bank, Depo sit No.C0104). And the following mutations or deletions. That is, mutations from arginine at position 175 to histidine, mutations from arginine at position 248 to tryptophan, or mutations from arginine at position 273 to histidine, which are mutations found in high ⁇ TO in human cancers ( The mutant P53 gene can be obtained by applying Lasky T. et a 1., Environ. Health Perspect., 104, 1324-1331 (1996)) or the like at the gene level.
  • the portion other than amino acid residues 302 to 393 (Mol. Cell. Biol., 12, p5 581-5592 (1992)), which is a region involved in the polymerization (tetramer formation) of p53,
  • the mutant p53 gene By deleting at the gene level, the above-mentioned deleted p53 gene can be obtained.
  • the normal type p53 gene Japanese Cancer Research Resources Bank, Deposit No. C0104
  • the 5 'side was set so that the mutation would enter the target site.
  • the primer and the 3 '* 3 ⁇ 4 ⁇ "primer of the normal P53 gene, and the 3'-side primer and the 5'-end primer of the normal p53 gene which were designed to introduce mutations into the target site, respectively PCR reaction, and then, to ligate the amplified fragments on the 5 'and 3' sides, mix both fragments, and perform PCR using primers on the 5 'and 3' sides of the normal P53 gene. Re-amplification to obtain the desired mutant p53 gene.
  • acquisition of a deletion type p53 gene for example, a primer for amplifying the 302nd to 393rd positions of ⁇ 53 may be prepared and amplified by a PCR reaction according to a conventional method.
  • Variant or deletion type P 5 3 gene mutant P 5 3 gene and the deletion type obtained in order to obtain a transformant 3 ⁇ 4 ⁇ ⁇ 3 ⁇ 4 ⁇ vesicles were expressed transliteration p 5 in Step A 3 gene p CAG GS (Gene, 108, P 193-200 ( 1991)) was inserted into a mammalian expression base Kuta one such building a ⁇ example onset expression vector, which was introduced into human normal cultured cells, and culture may be When PCAGGS is used as an expression vector, a blasticidin S resistance gene (bsr) may be introduced in advance in order to reduce the size of the transformed cells by adding a drug.
  • bsr blasticidin S resistance gene
  • the human normal cultured cells to be used may be any human normal cultured cells, but examples include human normal lung double blast cell line, HEL 299 (Dainippon Pharmaceutical).
  • Phosphoric acid co-precipitation method, ribosome DNA molecules can be introduced using standard methods (ribosome method, lipofectin method, lipofectamine method, HV J-ribosome method), electrophoresis method, microinjection method, etc.
  • Sffl vesicles i, for example, can be selected by adding a drug such as 2 g ⁇ 1 of blasticidin S).
  • a transformed cell overexpressing the mutant or deleted P53 gene By culturing the transformed MB vesicles prepared as described above, a transformed cell overexpressing the mutant or deleted P53 gene can be obtained.
  • p53 is known to function by forming a tetramer
  • normal tetramerization is achieved by expressing mutant or deleted P53 in f! j in the transformed vesicle. Inhibition of body formation and consequent inactivation of normal p53 function. Inactivation of p53 function maintains cell division compared to control transformed cells into which only one vector has been introduced.
  • Preparation of total RNA contained in step B It may be performed according to a conventional method.
  • RNA degrading cells by exposing cells in the presence of a surfactant such as SDS, NP-40, Triton-X100, or phenol.
  • a surfactant such as SDS, NP-40, Triton-X100, or phenol.
  • cells are disrupted by a physical method such as a homogenizer and the cells are crushed with guanidine thiosinate, and then the total RNA is denatured with a cesium chloride density gradient.
  • the phenolic thigh (Oki Gua) Total RNA can be prepared by the diphenyl thiocyanate monophenol chromatography method).
  • RT kits such as RNAmap kit (GenHunter) were used.
  • the amplified fragment is labeled with [a- 35 S] d ATP, and subjected to 6% denaturing polyacrylamide gel electrophoresis. After electrophoresis, the gel is evaporated to dryness, and P53-inactivated bffl cells (mutated or deleted P53) are compared to normal P53-transformed cells (cells into which only the vector has been introduced).
  • the DNA fragment After detecting DNA whose expression has been increased in the transfected cells, that is, DNA corresponding to the target p53 inactivation-specific gene, the DNA fragment is recovered from the gel. Then, after re-amplification using PCR again, the PCR fragments are collected, introduced into a PCR clone vector such as pT7Blue (R) T (Novagen), and the nucleotide sequence is determined according to a conventional method. I do. In this manner, a DNA fragment of a gene that is specifically expressed by inactivating P53 can be obtained.
  • pT7Blue (R) T Novagen
  • Step D This is for confirming the expression of the DNA selected in Step C.
  • an appropriate primer portion was set based on the salt of the clone obtained, and the total RNA of the normal (mutated vector), mutant and deleted p53 gene-transformed cells was determined.
  • a method of labeling the DNA fragment in the presence of [a- 32 P] dCTP or labeling the DNA fragment with a primer labeled at the end of the primer to detect the DNA fragment amplified to It is simple and convenient.
  • the amplification frequency set in this way is preferably 16 to 22 times $.
  • step E After cloning of the full-length cDNA (gene) in step E, the expression in each human MffiM was examined. Using a DNA fragment as a probe, The full-length cDNA can be cloned. Preparation of a cDNA library (Use a commercially available cDNA synthesis kit to convert the mRNA from the origin into type I. A human tissue-derived cDNA library (use a commercially available cDNA library) Is also possible.
  • the gene of the present invention together with the ⁇ of the above (a), a force which also has the characteristic of “(b) an increase in expression s ′ in cancer fibers compared to normal fibers” m E.
  • RNA prepared from tumors 5 and non-tumor of the same patient for example, Hum an Tumor Panel B lots of In Vitrogen, etc.
  • RNA prepared from the same fiber of a patient and a healthy person by performing a lino-san blot analysis using a conventional method.
  • the DNA comprising at least a continuous sequence of at least 17 bases of the gene obtained as described above is the ⁇ DNA '' of the present invention, which is an active ingredient of a diagnostic agent for cancer, and the mRNA of the fia fi gene is As long as its presence can be specifically detected, it may be single-stranded or double-stranded, and may be any length of DNA at any position in the gene. Further, the DNA may be labeled such that the single-stranded or double-stranded DNA can be diagnosed. Regarding what kind of DNA can specifically detect the presence of the corresponding mRNA of the pre-S gene, it can be easily performed by actually performing the PCR method and the hybridization method as described below. You can judge it.
  • At least 17 bases is stochastically based on the fact that at least 17 bases are sufficient to identify one gene. If such a DNA is short, it can be synthesized using a DNA synthesizer, if it is long, it can be prepared by PCR, or ii if there is an appropriate restriction enzyme site, it can be prepared using S. it can.
  • DNA of the present invention include the genes having the above-mentioned difficulties (a) and (b) and containing the base sequence described in any of the following: Single-stranded or double-stranded DNA consisting of at least 17 nucleotides of reverse strand, or Is the value of these characteristics.
  • the nucleotide sequences described in SEQ ID NOs: 14 to 29 are nucleotide sequences corresponding to a part of the novel gene obtained by the above A to E.
  • a gene containing the nucleotide sequence of any one of SEQ ID NOs: 14 to 29 can be cloned according to the method described in A to E in the above-mentioned H.
  • SEQ ID NO: 14 to SEQ ID NO: 29 By using an appropriate part of the DNA as a hybridization probe based on the body of the salt, and screening a cDNA library derived from a cell that expresses the DNA well. I can get it. The specific method at that time can be performed by referring to a basic book such as ⁇ Molecular Cloning 2nd Edt., Cold Spring Harbor Laboratory Press (1989).
  • a single strand or a single strand capable of specifically detecting the corresponding mRNA of the IRG27 gene consisting of SEQ ID NO: 3 to SEQ ID NO: 5 examples include double-stranded DNA, or ⁇ ⁇ 'of these DNAs. More specifically (a single-stranded or double-stranded DNA consisting of at least the 17-base sequence of the IRG27 gene, or a target I ⁇ thereof.
  • SEQ ID NOs: 3 and 4 The nucleotide sequence of the human IRG27 gene, which has the same nucleotide sequence except that both nucleotide sequences in the untranslated region are partially different from those of the human IRG27 gene.
  • nucleotide sequences of the mouse IRG27 gene These are the nucleotide sequences of the mouse IRG27 gene These genes can be obtained by the methods described in the above-mentioned steps A to E. Also, an appropriate probe is prepared based on the sequence information of SEQ ID NOS: 3 to 5, for example, from leukocytes. Cloning can also be achieved by screening the cDNA library of IRG27. In addition, the IRG27 gene can be cloned from the known HEM45 gene (accession No. U88964; Pent ecost BT, J. Steroid). Bio chem. Mo l. Bio l., 64, 25-33, 1998) and the same sequence (SEQ ID NO: 3 at positions 522 and 711). I can create the gene for IRG27.
  • allelic variants or genetic polymorphisms may exist in the IRG27 gene described in SEQ ID NO: 3 to SEQ ID NO: 5, and inheritance of the allelic variants or genetic polymorphisms is also possible.
  • DNA consisting of at least a 17-strand assassin and its indicator can also be used as an active ingredient in cancer diagnostics.
  • the DNA of the present invention is used as a probe for the reaction of PCR or a primer for the reaction of PCR for diagnosing cancer.
  • a preferred length is from 17 bases to 50 salts Sgj3 ⁇ 4.
  • a preferred length of ⁇ used as a probe for hybridization is a length S of 50 to 500 bases.
  • PCR primers include a set of PCR primers derived from the IRG27 gene described in ⁇ , ⁇ or C below, or a set of primers consisting of a sequence of at least 17 bases or more of these primers. No.
  • the DNA of the present invention By dissolving the DNA of the present invention in an appropriate buffer that does not hinder the reaction, it can be used as an active ingredient of a diagnostic agent for cancer.
  • a diagnostic agent for cancer for example, it is Rikikawa no to use in the form of a kit that also contains transcriptase, Taq polymerase, dNTP, reaction stop solution, etc.
  • Methods for diagnosing cancer using the diagnostic agent include the following methods.
  • the diagnostic method of the above 1) and 2) can be performed based on a basic book such as ( ⁇ Molecular Cloning 2nd Edt., Cold Spring Harbor Laboratory Press (1989)).
  • the primer DNA of the present invention is synthesized by a conventional method, and this is used as a diagnostic agent.
  • total RNA or poly (A) RNA is prepared from 3 ⁇ 4JM cells, blood, urine, etc. by the method described above, and this is used as type ⁇ . Is prepared.
  • the preparation of the single-stranded cDNA can be easily performed by using, for example, ⁇ Superscript pre-Sir 1 cation system (Life Technologies, Gaithersburg, MD). After that, the primer is added and the PCR reaction is carried out in the usual manner.
  • the PCR reaction conditions include, for example, 30 cycles of 95 ° C for 1 minute, 60 ° C for 1 minute, and 72 ° C for 2 minutes, followed by heating at 72 ° C for 10 minutes. Is electrophoresed on a suitable agarose gel to detect the presence or absence of the expression of mRNA of IRG27.
  • a measurement method based on the following principle, which is frequently used in clinical diagnosis, is based on the PCR method.
  • RNA is extracted and purified from blood or the like in the same manner as described above, and amplification (PCR reaction) of the target sample using the biotinylated primer is performed in the same manner as described above. Thereafter, the re-amplification product is unified with an alkaline solution and hybridized with the solid phase on which the complementary DNA probe is immobilized. After that, the solid phase is washed and reacted with enzyme-labeled avidin. After washing the solid phase, the enzyme substrate is added to perform a color reaction, and the absorbance is measured to detect the presence or absence of IRG27 mRNA.
  • PCR reaction PCR reaction
  • the ability to make a diagnosis is also possible by using the in situ PCR method (Fernandez et al., Mol. Carcinog, 20, 317-326, 1997).
  • the diagnosis by Northern plot of 2 for example, the following method can be used.
  • the single-stranded or double-stranded DNA of the present invention is labeled; Prepare and use this as a diagnostic reagent Double-stranded DNA, for example, 32 P-labeled PCR reaction product prepared by the method described in 1) above, using the nick translation method or the random prime labeling method.
  • total RNA or poly (A) RNA is prepared from the subject's fibrous cells, blood, urine, etc.
  • RNA chip Furthermore, diagnosis using a DNA chip is also possible. That is, first, the DNA of the present invention is synthesized on a DNA chip. Next, total RNA or (poly (A) RNA is prepared from fiber cells, blood, urine, etc. for fiber, and this is labeled with fluorescence or the like. It is possible to diagnose cancer by detecting the fluorescence of DNA, etc.
  • the DNA chip to which the DNA or polynucleotide of the present invention is bound can be obtained by ordering from Affymetrix in the United States. It is possible, and individual specific means of the above-mentioned diagnostic method can be performed with reference to Nature Genetics, 21, 1-60 (1999) and the like.
  • the present invention is applied not only to detection and diagnosis using the primers and the probe, but also to tissue tissue hybridazion of tissue.
  • the solid DNA is derived from a gene induced by inactivation of p53.
  • DNA derived from a gene regulated by inactivation of P53 is also a similar cancer. It can be used as a diagnostic agent for
  • the genes whose expression is controlled by the inactivation of p53 are exactly the same except that the gene whose expression is specifically controlled by the inactivation of p53 is detected in the differential display in the step C. By going through steps A to E, it is possible to “close”.
  • the partial sequence of the novel gene thus found is shown in SEQ ID NO: 30 to SEQ ID NO: 1.
  • SEQ ID NO: 14 to SEQ ID NO: 29 disclosed herein are a group of DNAs whose expression is induced by inactivation of p53
  • SEQ ID NO: 30 to SEQ ID NO: 4. 1 is a group of DNAs whose expression is regulated by inactivation of p53.
  • the antibody specifically recognizes the antibody and the polypeptide encoded by the above-described gene of the present invention (hereinafter, sometimes referred to as the polypeptide of the present invention). That is, (a) expression is induced by inactivation of the tumor suppressor p53, and (b) the expression is increased in cancer S compared to normal.
  • An antibody that specifically recognizes a polypeptide is Specifically, an antibody capable of specifically recognizing a polypeptide encoded by a gene containing the nucleotide sequence described in any one of SEQ ID NO: 14 to NO: 29 is more preferable.
  • SEQ ID NO: 1 Antibodies specifically recognizing human IRG27 comprising the amino acid sequence described, mouse IRG27 comprising the amino acid sequence represented by SEQ ID NO: 2, or an allelic variant thereof.
  • antibodies can be easily prepared by the method described in, for example, Antibodies; A Laboratory Manual, Lane, HD et al., Cold Spring Harbor Laboratory Press (1989), New Cell Engineering ⁇ Protocol, Shujunsha (1993), etc. Produced. That is, the antibody of the present invention can be produced by appropriately immunizing an animal by a conventional method using the polypeptide of the present invention or a part thereof as an immunogen.
  • the immunogen (A) the polypeptide of the present invention, (B) a fusion protein of the polypeptide with GST, etc., (C) a conjugate of an oligopeptide comprising a part of the polypeptide with KLH, etc. I can do it.
  • the polypeptide of the present invention (A) is inserted into an appropriate expression vector, and the gene of the present invention is inserted into Escherichia coli or (Ono-cultured cell line).
  • the polypeptide can be obtained by preparing and purifying the polypeptide in large quantities, and the fusion protein of the above (B), for example, the gene of the invention of the present invention can be added to a GST fusion protein expression vector such as pGEX-6P-1 (Pharmacia). This is introduced into Escherichia coli to obtain a transformant, followed by disruption of the cells by a conventional method, extraction of the fusion protein, and purification by daltathione Sepharose 4B (Pharmacia) or the like.
  • pGEX-6P-1 Pharmacia
  • the conjugate of the above (C) can be obtained by mixing with oligoprotein after synthesis of the oligopeptide: ⁇ Specific examples of the conjugate in RG27 IRG27-A consisting of the portion from position 104 to position 127 of the amino acid sequence described in SEQ ID NO: 1, I RG27-B consisting of the portion from position 131 to position 153, from the portion from position 159 to position 181 Each of the following I RG27-C is conjugated to KLH.
  • the animal species to be immunized may be a rabbit, a mouse, a rat, a chicken, a rabbit, a donkey, a hidge, a rabbit, or a polyclonal antibody if the antibody specifically recognizes the polypeptide.
  • any of monoclonal antibodies may be used.
  • Specific examples of the Nada body include an antibody corresponding to I RG 27-C comprising the portion of the amino acid sequence of human I RG 27 shown in SEQ ID NO: 1 from position 159 to position 181.
  • Various antibody fragments can also be prepared based on the antibodies obtained as described above.
  • the body fragments such Yotsute pepsin digestion ⁇ of ⁇ Ru F (ab ') antibody 2 fragments, F (ab') 2 Fab 'fragments which can be ⁇ by reducing the disulfide bonds of the fragment, and
  • the use of papain and a reducing agent to transform antibodies into 2K Fab and iiFab fragments, which are humiliated, is also included in the scope of the present invention.
  • antibodies can be prepared based on these antibodies or antibody fragments.
  • the invitations ⁇ for example, chimeric antibodies, humanized antibodies, l-body
  • it can be prepared according to the method described in JP-A-6500 / 47, Nature, 522 (1986).
  • the antecedent or the dead fragment is labeled with an enzyme or the like.
  • Specific enzyme labeling methods include, for example, the daltaraldehyde method, the perioso method, the maleimide method, and the pyridyl disulfide.
  • Enzymes used for labeling include, for example, small intestine-alkaline phosphatase, horseradish peroxidase, etc.
  • the antibody, the antibody fragment, and the derivative thereof of the present invention can be used as a diagnostic agent for cancer.
  • the antibody or the like of the present invention can be used as an active ingredient of a cancer diagnostic agent by allowing the antibody or the like of the present invention to be present in an appropriate medium such as serum albumin-containing phosphorus solution (PH7.0) at night. .
  • PH7.0 serum albumin-containing phosphorus solution
  • it can be used in the form of a kit containing, for example, a brush-labeled secondary antibody, a color former, a color former, a stop solution, a standard product, and the like.
  • Examples of a method for performing an immunological diagnosis using the diagnostic agent of the present invention include, for example, solid-state fiber.
  • a method for detecting the presence of the polypeptide of the present invention in cells a bodily fluid containing blood or saliva or in other words, a method for detecting the presence of the polypeptide of the present invention can be mentioned, that is, cytotoxic T cells (CTLs) are induced in the body against human cancer cells, and the CTL cells are damaged, resulting in cancer. Since the polypeptide of the present invention, which is specifically expressed in cells, is released into the blood or urine, the polypeptide can be detected in blood, saliva or urine.
  • CTLs cytotoxic T cells
  • Specific detection methods include fluorescent # 3 ⁇ 4, Western 'plot, immunoprecipitation, Immunoassay (RIA), Lin immunoassay (ELI SA), etc. No.
  • normal ELISA or RIA imaging at the operative night including blood or saliva or at the age at which the polypeptide contained in urine is detected is also convenient. All of these diagnoses can be easily performed based on basic books such as enzyme immunoassays and the Medical School (1978).
  • the ELISA method it is simple and convenient to coat the plate with a primary antibody, bind the IRG27 present in the sample, and react with the two isotopes to detect the antibody bound to the IRG27.
  • anti-I RG27A IgG an antibody described in the I RG27-A portion
  • anti-I RG27B IgG an antibody against the I RG27-B portion
  • biotin kMl RG27C IgG an antibody that binds to the IRG27-C moiety
  • peroxidase-labeled streptavidin followed by a color reaction.
  • the same detection can be performed by using the anti-IRG27C IgG directly labeled with enzyme such as peroxidase or alkaline phosphatase.
  • FIG. 1 Figure HEL 299 cells (VECTOR in the figure) transfected with the vector alone, and HEL 299 cells (175H, 175H in the figure) transfected with the three mutant p53 and deletion p53 plasmids prepared in Example 1. 248W, 273H and 302-393) are electrophoretic photographs showing the results of differential display. Arrow band Corresponds to fragment 27.
  • FIG. 2 is an electrophoresis photograph showing the results of RT-PCR detecting the expression of the IRG27 gene in a vector-transfected cell and three types of mutant p53- and deletion-type p53 plasmid-transfected cells.
  • the lower part of the figure shows the results of a similar experiment using G3PDH as a control. IRG27 was subjected to electrophoresis of 22 cycles of the PCR product and G3PDH was subjected to 20 cycles of the PCR product.
  • FIG. 3 is an electrophoretic photograph showing the result of Northern blotting of the expression of the IRG27 gene in normal human fibers.
  • the RNA plots for a, b, and c were obtained using a: Human, b: Human II, and c: Human Immune System of MuOnti eT issue Nort B rn B lot of C ontech, respectively. Used. The arrow indicates the position of the signal of IRG27.
  • FIG. 4 is an electrophoresis photograph showing the results of Northern blot analysis of the expression of the IRG27 gene in each human cell line.
  • Human Cancell e Cell Line of Mu 1 tip 1 e Tis ssue No r the rn B l o t of C 1 o n t e ch was used.
  • HL60 is a pro-IS leukemia cell line
  • He La is a cervical carcinoma cell line
  • K562 is a chronic medullary leukemia cell line
  • MOLT 4 acute lymphoblastic leukemia cell line is an electrophoresis photograph showing the results of Northern blot analysis of the expression of the IRG27 gene in each human cell line.
  • Raj i a one-kit lymphoma cell line, SW480; a cell line, an A 549 glutamic carcinoma cell line, and G 361 a malignant melanoma cell line.
  • the arrow indicates the position of the signal of IRG27.
  • FIG. 5 is an electrophoretic photograph showing the results of Northern blot analysis of the expression of the IRG27 gene in the tumor part (T in the figure) and non-tumor part (N in the figure) of the cancer patient. Threads are shown on each lane.
  • FIG. 6 is an electrophoretic photograph showing the results of Northern blot analysis of the expression of the IRG27 gene in the tumor part (T in the figure) and the non-tumor part (N in the figure) of four cases of lung cancer patients.
  • FIG. 7 is an electrophoretic photograph showing the result of Western blot analysis using an anti-I RG27 antibody. Electrolyzed sample DLD-1 cell lysate of stable transformed cells in which an IRG27 expression vector was introduced into cells (IRG27 lane in the figure) This is a cell lysate of a stable transformed ⁇ ffl cell transfected with only a vector (vector lane in the figure).
  • anti-IRG27 antibodies three kinds of anti-IRG27 antibodies (A-2, B-2, C-2) before affinity purification and after affinity purification were used.
  • Fig. 8 is an electrophoresis photograph showing the results of Northern blotting and estamplotting of the expression of mRNA and protein of IRG27 in various human cell lines.
  • Coomassie protein used for Western plotting The results of staining with Priluent Blue are also shown at the bottom of the figure, where HEL299 and * WI38 are normal lung 2-fold # »blast cells and HepG2 is a liver cancer cell line.
  • 293 is a fetal kidney-derived plasma carcinoma cell line
  • He La is a cervical carcinoma cell line
  • Saos-2 is an osteosarcoma Mffl vesicle line
  • U937 (! ⁇ Lymphoma).
  • Cell line, RD myofioma cell line, T24 bladder cancer cell line, ScaBER is bladder cancer cell line
  • DLD-1 is a general cell line
  • Raj i a kitlin follicular cell line
  • K U- 2 is a renal cancer cell lines.
  • FIG. 9 is a graph showing detection of IRG27 by the ELISA method using an anti-IRG27 antibody.
  • the abscissa indicates the values of the GST-fused IRG27 protein as an antigen and the control GST protein, and the ordinate indicates the absorbance.
  • the measured values when the detection antibody of 1 mg / m1 was used only for the GST protein are shown.
  • pro Sp 53 containing a 1.9 Kb normal p53 cDNA gene (provided by Dr. Kiyomitsu Nemoto, Shizuoka Prefectural University; generally, D-marked osit No. from Japanese Cancer Research Resources Bank) (Available as CO 104) or pBS-p53 in which the gene contained in the EcoRlZBamHI cut fragment in the plasmid was introduced into pBuescriptII-SK (+) (Stratagene).
  • PCR was performed to amplify the DNA fragments in the 5 'H region and the 3' region of p53.
  • DNA fragments of the desired length were purified by agarose electrophoresis. PCR was performed by a conventional method using the obtained two types of DNA fragments, the p53Xho primer and the p53term primer.
  • the amplified DNA fragment was subjected to 1% agarose Geso HI electrophoresis, and a DNA fragment of a desired length was recovered, cut with XhoI, and introduced into pB1uescript II SK (+). 248th and 27th
  • the p53 gene fragment having a mutation at the amino acid at position 3 was also introduced into pB1uescript II SK (+) using the corresponding primer in the same manner as described above.
  • the normal P53 cDNA was also amplified using primers (p53te rm and p53Xho, respectively) with XhoI cleavage sequences added to the 3 'and 5' sides of the open reading frame, and And introduced it into pB 1 ue script II SK (+).
  • the DNA of the clone mutated at position 175 had a deletion of about 200 bp at the 5 'side, and the mutation potential at positions 248 and 273 was i.
  • the DNA of the clone containing the DNA had a deletion of 29 bp each on the 5 'side. Therefore, the 5′-side region of the normal P53 gene was ligated using the NcoI cleavage site contained in the p53 gene to obtain each mutant P53 gene of interest.
  • a deleted p53 gene consisting only of the p53 domain (nuclear translocation, tetramer formation, non-specific single-stranded DNA binding domain) is also produced.
  • a primer pMINI: GTT AAC TCG AGC CAC CAT GGG GAG CAC TAA GCG AGC ACT GCC CM C CA
  • PCR was performed using the 3 ′ primer (p53terra) of the open reading frame of the normal p53 gene.
  • the pB1uescript II recombinant vector containing the mutant P53 DNA and the pCAGGS thread male vector containing the deleted P53 DNA obtained as described above are cut at X1101 to cut the insert DNA. separated. Insert these insert DNAs into Pvu II—EcoR I DNA fragment containing the blasticidin S resistance gene (bsr) expression unit of p SV2 — bsr (Health Pharmaceutical Co., Ltd.) into S a 1 I in a pCAGGS vector Each was introduced into the XhoI site of the inserted pCAGGS-bsr. In the clones obtained, 175 amino acid residues were mutated from arginine to histidine.
  • Three mutant p53 plasmids (pCAGGS-bsr-175H, pCAGGS-bsr-248W, pCAGGS-bsr-273H) and deletion p53 plasmid (pCAGGS-bsr-p53-302-393), respectively 2.2 ⁇ 10 6 human normal lung 2 ⁇ ⁇ «
  • the application conditions were 300 V, 0.75 kV / cm, a pulse width of 1000 ⁇ s, the number of pulses was 6 times, and a culture solution containing 2 ⁇ g / m 1 blasticidin S 24 hours later was selected. After 5 days from the start of selection, surviving transformed cells were collected. As a control, similar cells into which vector-1 (pCAG GS-b sr) was introduced were also prepared.
  • the recovered transformed cells 0. 5% NP- 40, 1 OmM T ris- HC 1 (pH8. 6), 14 OmM NaC l, Karoe a 1. 5mM MgG l 2, 1000UZ ml RNa sei nh ibitor the re supernatant by the suspension after centrifugation was collected, equal amounts of 0. 2M T ris -HC 1 (P H7. 5), 2% SDS, 25mM EDT a, 0. 3M NaC l, 200 ⁇ g / m 1 Proteinase K was added, and the mixture was heated at 37 ° C. for 30 minutes. After adding and extracting an equal amount of phenol: chloroform: isoamyl alcohol (25: 24: 1), total RNA was recovered with ethanol-5 and used in the following procedure. Imperial example 3
  • RNA derived from the transformed cells obtained in Example 2 according to the protocol of RNAmapkits A to D from GenHunter.
  • the RT reaction was carried out using the ⁇ type.
  • PCR was performed using a total of 80 primer sets.
  • PCR reaction Using GeneAmp PCR system 9600 manufactured by Perkin E 1mer, 94 ° Cx 20 sec -48 ° Cx 1 min-72 ° Cx 30 sec 10 cycles, 94 ° Cx 20 sec- 35 cycles of 40 ° C 1 min-72 ° C x 30 sec were performed, heated at 72 ° C for 5 min, and then cooled to 4 ° C.
  • PCR solution subjected to the thermal MS was electrophoresed on a 6% sequence denaturing gel (Long Ranger 6% premix gel; FMC). After drying by JE, X-ray film (Bio Max MR; Kodak) was Exposure for ⁇ 3 days.
  • Figure 1 shows the results of autoradiography. In addition to DNA fragments that appear specifically in P53-inactivated cells, we also searched for DNA fragments whose expression decreased with p53 inactivation, and matched the target band in the autoradiogram. The dried gel portion was cut out. Table 1 shows the strength of expression of each selected DNA fragment in each medullary cell.
  • Each excised gel portion was immersed in 100 1 water for 10 minutes, heated at 100 ° C for 15 minutes, centrifuged, and 50 g of daricogen was added to the supernatant, and the amplification product was recovered with ethanol.
  • the recovered DNA solution re-amplify by PCR, purify the DNA fragment in a SUPREC-02P Gongai 3 ⁇ 4 centrifuge tube (Takara), and use the plasmid vector pT7B1ue (R) (Nov age n ).
  • the nucleotide sequence of the clone group containing the obtained 64 types of fragments was determined, and a homology search was performed using a GenBank ZEMBL gene database (DNAS IS CD-ROM 033; Hitachi Software Engineering Co., Ltd.). Various new or known genes have been identified. Table 2 summarizes the results. “Nove 1” in the table corresponds to a novel gene. Among these novel genes, the nucleotide sequence of DNA that appears specifically in P53-inactivated cells is shown in SEQ ID NOS: 14 to 29, and the nucleotide sequence of DNA that decreases with p53 inactivation is shown in SEQ ID NO: : 30 to SEQ ID NO: 41.
  • p21 WAF-1 is derived from p53 by the expression level of the gene by% 1.
  • the differential display used in the present invention was determined to be suitable for unraveling genes whose expression increases or decreases due to inactivation of P53.
  • RNA as type II RT-PCR was performed.
  • the 5 'end of the primer was labeled with 32 P, and the number of amplification cycles was changed to 16, 18, 20, and 22 times.
  • electrophoresis of the PCR solution and measurement of the signal intensity of the amplified DNA fragment it was shown that the DNA fragment of G3PDH was microamplified in any of the transformed cells in 16 to 22 cycles. It was confirmed that the total RNA samples used for RT-PCR were almost equivalent.
  • the DNA sequence corresponding to fragment 27 was found from the EST database (accession on No. AA 150500 and accession on No. AA 1567 04), and the primers that can specifically detect the gene corresponding to fragment 27 were used. The primary sequence was selected and the same RT-PCR was performed. When the number of cycles was increased from 18 to 22, the logarithmic amplification was shown. The primer used (see below).
  • Northern blotting was carried out by a conventional method using a filter from which RNA derived from each cell and cells was blotted and purchased from C1onetech.
  • Figure 3 shows the results of examining the expression in various human normal threads. Strong expression and expression of IRG27 were observed in lymphoid fibers such as peripheral blood leukocytes, spleen, and thymus. Fibers other than the lymphoid fiber were relatively strong in the small intestine, but this may be due to the small intestine's ability to possess its own immune fibers (lymphocytes). In normal humans except for the above-mentioned threadwork, IRG27 was not expressed, or even if it was expressed, the expression was extremely low. The size of the mRNA was 0.9 Kb, and transcripts of 1.8 Kb, 3 Kb, and 4.5 Kb were detected, though weakly.
  • Fig. 4 shows the results of examining the expression in various human cancer cell lines. Expression was observed in most of the cancer cell lines examined. In particular, high frequency expression was observed in a lymphoma-derived cell line (Raj i), and strong expression was also observed in a large cell line (SW480) and a cervical lining cell line (HeLa). Furthermore, the expression was high in the fetal liver thread, but extremely low in the adult liver (Fig. 3). This means that the IRG27 gene This suggests that, like Rikiichi CE A, he is closely related to Ganji-Dani. Difficult case 6
  • IRG27 peripheral blood leukocytes. Therefore, screening of IRG27 cDNA was performed using a human leukocyte cDNA library (Gibco BRL). 2. RESULTS subjected to colony High Priestess die See Chillon using the probes prepared in Example 5 to 7x l 0 6 colonies, 8 clones by three subscription-learning is selected.
  • nucleotide sequences were determined for three clones, I RG27-3-1, I RG27-4-1, and I RG27-9-11, each having an insertion sequence of 1 Kb.
  • the open reading frame portions corresponding to the 181 amino acid residues of the three clones were identical.
  • the sequence 5 ′ upstream of the start codon of IRG27-4-1 was different from that of IRG27-3-1 and IRG27-9-1.
  • the nucleotide sequences contained in the clones I RG27-3-1 and IRG27-4-1 are shown in SEQ ID NOs: 3 and 4.
  • the amino acid sequence deduced from these nucleotide sequences is shown in SEQ ID NO: 1. It should be noted that PCR using body DNA as a type III is expected to be caused by the above-mentioned DNA sequence difference a 1 t rennativessplicnicg.
  • HEM45 is known to be upregulated by estrogen
  • ISG20 is known to be upregulated by type I and II interferon.
  • Difficult case 7 is not known that the expression is increased by inactivating ⁇ 53.
  • Partial sequence of mouse type I RG27 (ml RG27) gene Deduced from EST database, base deletion in the region corresponding to open reading frame of hI RG27, translated into amino acid sequence as is Then, the protein encoded by the mIRG27 gene becomes a polypeptide having a C-terminal deletion compared to the hIRG27 protein. Therefore, in order to clarify the amino acid sequence of the protein encoded by the mlRG27 gene, a primer was set based on the nucleotide sequence of the EST database, and a mouse spleen cDNA library (C1tech) The DNA fragment was amplified by PCR using the ⁇ as a ⁇ , and introduced into pGEM_Teasy Vector (Promega).
  • nucleotide sequence was determined by the direct method using the amplified PCR fragment, and the correct nucleotide sequence of the mlRG27c DNA gene was determined.
  • IRG27 expression was elevated in human, ovarian, and fallopian tube cancers.
  • Fig. 6 the rise of IRG27 was observed.
  • Tables 3 and 4 summarize the rise of S ⁇ in the tumor area. (In the table, the more Byeons, the greater the expression in the tumor area than in the non-tumor area. This indicates that the expression is lower in the iiffl's tumor than in the non-tumor's).
  • Table 3 corresponds to the results in Figure 5
  • Table 4 corresponds to the results in Figure 6.
  • the expression of the IRG27 gene which was cloned as a gene that increases with the inactivation of p53, was observed in tumors of ⁇ 70% 3 ⁇ 48.
  • the proportion that [rho 5 3 months mutations in cancer patients than the height (about 5 0%, Cel l, 88 , P 323-331 (1997)) was a value.
  • the renal cancer (20 cases) 2 cases liver cancer, thyroid cancer, parotid gland cancer, ureteral cancer, bladder, uterine cancer, ovarian cancer (the tendency was remarkable.
  • the frequency was 45%.
  • I RG27-A consisting of the portion at positions 104 to 127 of the amino acid sequence described in SEQ ID NO: 1
  • I RG27-B consisting of the portion at positions 131 to 153, and position 159 To 181st position of IRG27-C were synthesized.
  • the oligopeptide was conjugated to KLH, and this was used as an antigen to immunize rabbits in the usual manner. Egrets were prepared.
  • RG27 protein was recognized.
  • FIG. 7 shows the results of Western plot clarification using ⁇ -purified and purified antibodies.
  • RNA from various cells GI BCO-BRL was prepared using a Trizol kit. 20 g of total RNA is formalin-containing 1% agarose per ligation! / «Electrophoresis and transferred to NEN nylon membrane (Gene Screen P 1 us), then 1 MNaCl, 10% dextran Prehybridization was performed using 1% SDS, 50% formamide, and 100 ⁇ 6 g / ml salmon sperm DNA. Using the Nco IZS ac I fragment of IRG27 cDNA (SEQ ID NO: 3) labeled with 32 P using BcaBEST Labeling Kit from Takara as a probe, linogen hybridization was performed by a conventional method. I went to one session.
  • Washing was performed twice at room temperature for 10 minutes with 2 XSSC, twice at 60 ° C for 20 minutes with 2 XSSC and 1% SDS, and then at room temperature for 10 minutes with 0.1 x SSC and 0.1% SDS once. Detection was performed using Kodak's BI OMAX MS film.
  • Preparation of proteins from cells was performed by lysing the cells with 31.25 niM Tris-HCl (pH 6.8), 7.5% glycerol, and 2% SDS.
  • the protein iU3 ⁇ 4 was obtained using Pierce's BCA protein measurement kit. Were determined. Add 5% (V / V) 2-mercaptoethanol and 0.01% (W / V) BPB to the protein solution of No. 10, and add oat barley at 100 ° C for 5 minutes, 153 ⁇ 4SDS-polyacrylamide gel 1 / S It was subjected to electrophoresis.
  • the IRG protein used in the present invention was prepared as a fusion protein with GST as follows. That is, first, the cDNA of human I RG 27 (SEQ ID NO: 3) cloned in Example 6 was inserted into pGEX-6 ⁇ ⁇ -1 (Pharmacia) so that the reading frame matched it. A GST fusion I RG27 protein expression plasmid was prepared, and then the host E. coli JM109 (Toyobo) was transformed with the expression plasmid and cultured at 37 ° C. 1 mM IPTG was added and the cells were cultured for 1 hour * 3 ⁇ 4 and the cells were recirculated 4.
  • the cells were buffered with PBS containing ImM PMSF, 1 ⁇ g / m 1 pepstatin A, and lgZml leptin. — Suspended in E (PBS, 5mM EDTA), sonicated, and added Triton X-100 to a final concentration of 1% as a control. Glutathione Sepharose 4B (Pharmacia) was added to the supernatant, and GST-fused IRG 27 proteins were bound. The daltathione Sepharose was washed three times with PBS-E, and the GST-fused IRG27 protein was eluted with 50 mM TrisHCl (pH 8.0) buffer containing lQmM original glutathione. The purified GST fusion I RG27 protein was quantified using the Protein Assay Kit (BI ORAD).
  • the ELISA method was performed as follows.
  • the anti-I RG27 B-2 IgG prepared in Example 9 was adsorbed onto a 96-well plate, Immunoplate II (Nunc), and then the GST fusion I prepared at various concentrations prepared above. RG27 was reacted. Subsequently, the biotin bMl RG 27 C-2IgG prepared using the biotin labeling kit of Boehringer Mannheim was reacted, and peroxidase-labeled streptavidin (B10 SOURCE I NTERNAT ION AL) After the reaction, a color reaction was carried out using TMB Microcell II Perox i das e Sub strat e System (KPL). The results are shown in FIG.
  • the anti-IRG27 antibody of the present invention did not react with GST, but reacted with GST-fused IRG27 in a manner dependent on the antigen iJS and the detection antibody. From these results, the ability to perform ELISA using the anti-IRG27 antibody of the present invention became clear.
  • a human lymphoma-derived cancer cell such as Raji cell is administered to mouse J »such as C57B6, and the cancer cell is proliferated by.
  • CTL cytotoxic T cell
  • IRG27 derived from human cancer cells is released into fil and urine. Therefore, the blood and urine can be woven at any time after inoculation of the cancer cells and subjected to the ELISA method described in Example 11 above, whereby the protein of IRG27 can be detected.
  • Example 11 Perform EL ISA Significantly detect IRG27 protein in S cancer patients compared to healthy individuals, so that it is possible to select patients with cancer from among the examinees.
  • the 74th and 87th nucleotides in the nucleotide sequence of SEQ ID NO: 20 could not be determined.
  • the 24th, 34th, 45th, 65th, 66th, 70th, 73rd, 74th, 84th, 84th, and 86th positions of the nucleotide sequence described in SEQ ID NO: 21 The 89th, 109th, 114th and 123rd bases The base could not be determined.
  • the 17th, 62nd, 99th, 11th, 125th, 129th and 170th bases of the base sequence described in SEQ ID NO: 23 could not be determined.
  • the eighth, 41st and 87th amino acids in the nucleotide sequence of SEQ ID NO: 26 The base could not be determined.
  • the 63rd, 75th, 108th, 158th, 179th and 189th bases of the base sequence described in SEQ ID NO: 28 can be determined. No bases 15th, 28th, and 41st bases in the base sequence of SEQ ID NO: 30 I Bases that could not be determined.
  • Rooster No . bases described in 39. Bases No. 108, No. 157, No. 181, and No. 209 in base of rooster. These bases could not be determined. .
  • SEQ ID NO: 41 2nd 21st ⁇ S of the nucleotide sequence described in SEQ ID NO: 41 is a nucleotide that could not be determined.
  • Antibodies against the IRG27 gene of the present invention or a part thereof, or the IRG27 protein are useful for diagnosis of a wide variety of cancers.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux diagnostics du cancer, une méthode diagnostique, etc., par utilisation d'un gène codant pour un polypeptide dénommé IRG27 dont l'expression est induite par l'inactivation de p53 et est élevée dans plusieurs cancers se manifestant chez l'homme, tels que le cancer de l'oesophage, le cancer de l'estomac, le cancer du poumon, le cancer du rein, le cancer de la thyroïde, le cancer de la parotide, le cancer de l'uretère, le cancer de la vésicule, le cancer de l'utérus, le cancer du foie, le cancer du sein, le cancer de l'ovaire et le cancer des trompes. L'invention concerne également un anticorps contre IRG27.
PCT/JP2000/001796 1999-03-31 2000-03-23 Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique WO2000060073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9364199 1999-03-31
JP11/93641 1999-03-31

Publications (1)

Publication Number Publication Date
WO2000060073A1 true WO2000060073A1 (fr) 2000-10-12

Family

ID=14087999

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/001796 WO2000060073A1 (fr) 1999-03-31 2000-03-23 Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique

Country Status (1)

Country Link
WO (1) WO2000060073A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087349A1 (fr) * 2000-05-19 2001-11-22 Sumitomo Pharmaceuticals Company, Limited Agents carcinostatiques ou agents antiviraux contenant une proteine ou un gene irg27
WO2003023031A1 (fr) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques
WO2005093063A1 (fr) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. Kit pour diagnostic de cancer consistant et medicament pour therapie contre un cancer consistant
EP2169060A1 (fr) 2004-06-02 2010-03-31 alphaGEN Co., Ltd. Nouveau polypeptide utile pour diagnostiquer et pour traiter le cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN T. PENTECOST: "Expression and estrogen regulation of the HEM45 mRNA in human tumor lines and in the rat uterus", J. STEROID BIOCHEM. MOLEC. BIOL., vol. 64, no. 1/2, 1998, pages 25 - 33, XP002928832 *
CELINE GONGORA ET. AL.: "Molecular cloning of a new interferon-induced PML. nuclear body-associated protein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 31, 1997, pages 19457 - 19463, XP002928833 *
DATABASE BIOSIS GUSTAFSSON BRITT ET AL: "Overexpression of MDM2 in Acute Childhood Lymphoblastic Leukemia" *
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol. 15, no. 6, 1998, pages 519 - 526 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087349A1 (fr) * 2000-05-19 2001-11-22 Sumitomo Pharmaceuticals Company, Limited Agents carcinostatiques ou agents antiviraux contenant une proteine ou un gene irg27
WO2003023031A1 (fr) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques
WO2005093063A1 (fr) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. Kit pour diagnostic de cancer consistant et medicament pour therapie contre un cancer consistant
EP2169060A1 (fr) 2004-06-02 2010-03-31 alphaGEN Co., Ltd. Nouveau polypeptide utile pour diagnostiquer et pour traiter le cancer
US8222393B2 (en) 2004-06-02 2012-07-17 Tss Biotech Inc. Polypeptide useful for cancer diagnosis and treatment

Similar Documents

Publication Publication Date Title
KR101828290B1 (ko) 자궁내막암 마커
US7557204B2 (en) CUDR as biomarker for cancer progression and therapeutic response
JP4614472B2 (ja) 乳房の疾患の検出に有用な試薬および方法
CA2676179C (fr) Variantes d'epissages specifiques metastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
WO2003026493A2 (fr) Diagnostic et traitement de maladies induites par des mutations dans le gene cd72
JPH11507212A (ja) Ｄｎａ配列及びエンコードされた乳房に特異的な乳癌たんぱく質
WO2007026895A1 (fr) Kit et procédé pour détecter le cancer urothélial
JP2001523472A (ja) 乳房の疾患の検出に有用な試薬および方法
JP2001521744A (ja) 乳房の疾患の検出に有用な試薬および方法
JP7150018B2 (ja) 新規なｃｉｐ２ａバリアント及びその使用
WO2000060073A1 (fr) Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique
US20100330554A1 (en) Diagnostic kit for solid cancer and medicament for solid cancer therapy
JP4576168B2 (ja) 膀胱尿管逆流症または間質性膀胱炎の検査方法
US8349562B2 (en) Molecular markers for the diagnosis and treatment of tumors
JP4473870B2 (ja) 新規キメラ蛋白質およびそれをコードする遺伝子、並びに、これらの遺伝子と蛋白質を用いた白血病の判別手段
EP1621637A1 (fr) mRNA ou peptide ppGalNac-T6 comme marqueur pour la détection des cellules cancéreuses
KR101093508B1 (ko) 대장암 진단용 조성물 및 그 용도
JPWO2004061103A1 (ja) 新規タンパク質及びそれをコードする遺伝子
US7928188B2 (en) Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer
JP5354484B2 (ja) がん検出方法
JP2011079831A (ja) 癌の診断と治療において有用な新規ポリペプチド
KR20110036558A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036557A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036556A (ko) 대장암 진단용 조성물 및 그 용도
JP2010284135A (ja) 新規遺伝子ファミリーｅｃｓａ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609565

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase